DMD Celsis microsomes mean better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Postlind, H.
Right arrow Articles by Andersson, S. H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Postlind, H.
Right arrow Articles by Andersson, S. H. G.

Vol. 26, Issue 4, 289-293, April 1998

Tolterodine, a New Muscarinic Receptor Antagonist, Is Metabolized by Cytochromes P450 2D6 and 3A in Human Liver Microsomes

Hans Postlind, Åsa Danielson, Anders Lindgren, and Stig H. G. Andersson

Department of Drug Metabolism, Pharmacia & Upjohn AB

Tolterodine, a new muscarinic receptor antagonist, is metabolized via two pathways: oxidation of the 5-methyl group and dealkylation of the nitrogen. In an attempt to identify the specific cytochrome P450 enzymes involved in the metabolic pathway, tolterodine was incubated with microsomes from 10 different human liver samples where various cytochrome P450 activities had been rank ordered. Strong correlation was found between the formation of the 5-hydroxymethyl metabolite of tolterodine (5-HM) and CYP2D6 activity (r2, 0.87), as well as between the formation of N-dealkylated tolterodine and CYP3A activity (r2, 0.97). When tolterodine was incubated with human liver microsomes in the presence of compounds known to interact with different P450 isoforms, quinidine was found to be the strongest inhibitor of the formation of 5-HM. Ketoconazole and troleandomycin were found to be the strongest inhibitors of the formation of N-dealkylated tolterodine. A weak inhibitory effect on the formation of N-dealkylated tolterodine was found with sulfaphenazole, whereas tranylcypromine did not inhibit the formation of this metabolite. Microsomes from cells overexpressing CYP2D6 formed 5-HM, whereas N-dealkylated tolterodine was formed by microsomes expressing CYP2C9, -2C19, and -3A4. The Km for formation of N-dealkylated tolterodine by CYP3A4 was similar to that obtained in human liver microsomes and higher for CYP2C9 and -2C19. We conclude from these studies that the formation of 5-HM is catalyzed by CYP2D6 and that the formation of N-dealkylated tolterodine is predominantly catalyzed by CYP3A isoenzymes in human liver microsomes.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
J. P. Gibbs, R. Hyland, and K. Youdim
Minimizing Polymorphic Metabolism in Drug Discovery: Evaluation of the Utility of in Vitro Methods for Predicting Pharmacokinetic Consequences Associated with CYP2D6 Metabolism
Drug Metab. Dispos., September 1, 2006; 34(9): 1516 - 1522.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. J. Gardiner and E. J. Begg
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Dmochowski, A. Chen, G. Sathyan, S. MacDiarmid, S. Gidwani, and S. Gupta
Effect of the Proton Pump Inhibitor Omeprazole on the Pharmacokinetics of Extended-Release Formulations of Oxybutynin and Tolterodine
J. Clin. Pharmacol., August 1, 2005; 45(8): 961 - 968.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Teyssier, L. Guenot, M. Suschetet, and M.-H. Siess
Metabolism of Diallyl Disulfide by Human Liver Microsomal Cytochromes P-450 and Flavin-Containing Monooxygenases
Drug Metab. Dispos., July 1, 1999; 27(7): 835 - 841.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
S. H. G. Andersson, A. Lindgren, and H. Postlind
Biotransformation of Tolterodine, a New Muscarinic Receptor Antagonist, in Mice, Rats, and Dogs
Drug Metab. Dispos., June 1, 1998; 26(6): 528 - 535.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
F. Hosseinpour and K. Wikvall
Porcine Microsomal Vitamin D3 25-Hydroxylase (CYP2D25). CATALYTIC PROPERTIES, TISSUE DISTRIBUTION, AND COMPARISON WITH HUMAN CYP2D6
J. Biol. Chem., October 27, 2000; 275(44): 34650 - 34655.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.